… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board. Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the Company’s …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … excited by the potential of our next-generation Axiomer RNAediting technology. In addition to using this platform to …
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p